

## Abstract Submission Guidelines

Authors are invited to submit abstracts for the upcoming 23rd International Myeloma Society Annual Meeting being held September 23-26, 2026, in Glasgow, Scotland.

During the prestigious International Myeloma Society Annual Meeting (IMS Annual), myeloma experts from around the world gather to discuss basic, preclinical, and clinical aspects in the biology and treatment of multiple myeloma. The scientific program will include oral presentations, consensus panels, debates on controversial and current arguments, and poster abstracts. Abstracts presenting new research and/or furthering existing studies in the biology and treatment of multiple myeloma are encouraged. Be sure to complete all steps and to finalize the abstract submission. Only finalized submissions will be evaluated. Note that you will receive an email stating your submission is complete. If you did not receive this email, please verify that it is complete and not saved as a draft.

All abstracts will be blinded and peer reviewed. Abstracts will be selected based on the relevance of the topic, scientific merit, quality of the study, impact of the results on further studies and/or clinical practice, interest to IMS Annual attendees, and available space. Authors will be notified in early July 2026 if their abstract has been accepted for presentation at the Meeting. Presenting authors will be required to register for the 23rd International Myeloma Society Annual Meeting, and all registration, travel, and related expenses are the sole responsibility of the presenting author.

**The abstract submission deadline is Sunday, May 31, 2026, 11:59 pm EST.**

### Important Dates

May 31, 2026	Abstract Submission Deadline
Early July 2026	Abstract Notification
July 6, 2026	Abstract Acceptance Deadline
	<i>Note, if abstract is selected and an acceptance is not received by this deadline, the abstract will automatically be withdrawn.</i>
July 6, 2026	Late-Breaking Abstract Submission Open
August 10, 2026	Late-Breaking Abstract Submission Closes (at 11:59 pm EST (GMT+5))
Mid-August 2026	Late-Breaking Abstract Notification

### Submission Formats

Oral Abstract – A limited number of high-ranking abstracts will be selected for oral presentation.

Poster Abstract – Accepted poster abstracts will be presented during dedicated poster sessions. Presenting authors are required to prepare and display a physical poster, be present with their physical poster during their assigned poster session, and upload an electronic version of their poster for viewing in the mobile app and at onsite ePoster viewing kiosks.

Nursing and Allied Health Abstract – Nursing and Allied Health abstracts are submitted online through the abstract submission site. Please select "Nursing and Allied Health" for both the Presentation Format and Abstract Track. All abstracts submitted for the Nursing and Allied Health Symposium will be eligible to be considered for the Nursing and Allied Health Symposium Abstract Award.

### **Authors and Presenters**

---

Authors must include the name, e-mail address, institutional affiliation, and location for all co-authors. A maximum of 25 co-authors may be listed per abstract. If an author's name appears on multiple abstracts, it must be entered identically for each abstract. An automated email notification will be sent to each author prompting them to log in and verify their information.

The submitter must designate one presenting author for each abstract. Authors submitting multiple abstracts should plan for alternative presenters, who must be listed as co-authors, if more than one abstract is accepted and presentation times overlap.

All oral abstract presenters are required to disclose any financial and non-financial conflicts of interests to satisfy continuing education requirements.

### Responsibility of Abstract Submitters

- Submission of an abstract constitutes a commitment by the author(s) to present if accepted.
- Authors are responsible for providing a substitute presenter if the presenting author is unable to attend.
- Encore abstracts are permitted; however, the inclusion of new or expanded data is strongly encouraged, and scoring will reflect the degree to which the work extends prior presentations.
- By submitting an abstract, the authors certify that e written consent has been obtained for the use of any recognizable images included in posters or presentations.
- All original research involving human subjects or animal studies must comply with internationally accepted standards for the conduct of research and be approved by a regionally appropriate oversight body (e.g., Institutional Review Board (IRB) or Animal Care and Use Committee).

### Responsibility of Accepted Abstract Presenters

- Present the abstract as scheduled.
- Ensure that all required financial and non-financial relationship disclosures have been submitted. Disclosure of financial relationships with commercial entities is required for the presenting author and his/her spouse and institution (oral abstract presenters only).
- Verbally announce disclosures prior to the presentation.
- Log in to the abstract submission system to confirm acceptance of the presentation and review the presentation guidelines.
- Prepare all abstract presentation materials in English, the official language of the IMS Annual Meeting.
- Register for the 23rd IMS Annual Meeting (note, presenting authors are responsible for all registration fees and personal expenses related to the meeting).

- Presentation date and time assignments will be communicated in mid to late August. Presenters are expected to be available for the full duration of the IMS Annual Meeting, as abstract sessions occur Wednesday through Saturday, with many oral presentations scheduled for Saturday. Date or time change requests cannot be accommodated.

### **Late-Breaking Abstracts**

---

**Submission Window: July 6, 2026 - August 10, 2026, 11:59 pm Eastern Standard Time (GMT -5)**

Late-breaking abstracts are intended for high-impact studies whose data were not available at the time of the standard abstract deadline, such as clinical trials with interim or final analyses occurring after the deadline. While not limited to clinical trials, these submissions should present important, timely findings with clear relevance to the field. A limited number of these abstracts will be selected for oral presentation; remaining high-quality submissions may be accepted as poster presentations.

### **Abstract Embargo Policy**

---

In compliance with the U.S. Securities and Exchange Commission's Regulation FD (Fair Disclosure), accepted abstracts will be made available online in advance of the meeting and published as a special supplement to the *Clinical Lymphoma, Myeloma, & Leukemia* Journal.

Any coverage or dissemination of information that goes beyond the abstract title, authors, and scheduled presentation date and time --including results, findings, analyses, commentary, interviews, press materials, or updated data from study investigators, sponsors, or affiliated organizations—is subject to embargo under the following conditions:

- Oral presentations: The embargo lifts at the start time of the session in which the abstract is presented.
- Poster presentations: The embargo lifts when the poster session containing the poster abstract opens for viewing the morning of the scheduled presentation day.

Abstracts selected for presentation at the 23rd IMS Annual Meeting will be available online approximately three weeks prior to the Meeting. While abstracts are made available in advance to assist attendees in planning their itineraries, the embargo policy remains in effect until the applicable lift time.

### **Media Guidance**

Authors, institutions, and sponsors may share the abstract title and presentation details (authors, date, time, and format) prior to the embargo lift. Press releases, media briefings, interviews, investor communications, or public statements that include or reference abstract data, results, interpretations, or conclusions must not be distributed until the embargo has lifted in accordance with the presentation format.

## Abstract Elements

---

Below is a list of the sections required for all abstracts. Do not include any identifying information in the body or title of the abstract.

- Title - The title should be concise (maximum 200 characters) but clearly describe the nature of the presentation. Omit author names, degrees, titles, institutional appointments, or any other identifying information in the title.
- Abstract Type – The submitter should select the type of abstract they are submitting.
  - Basic – Laboratory-based or pre-clinical research advancing understanding of disease biology without direct patient involvement.
  - Clinical – Patient-based research evaluating diagnosis, treatment, safety, outcomes, or quality of life, with direct relevance to clinical care and patient management.
  - Translational – Research linking biological or mechanistic findings to patient-based data, using biomarkers or correlative science.
- Presentation Format
  - Oral Abstract – A limited number of high-ranking abstracts will be selected for oral presentation.
  - Poster Abstract – Accepted poster abstracts will be presented during dedicated poster sessions. Presenter authors are required to prepare and display a physical poster, be present at their poster during the listed poster presentation time for their assigned session, and upload an electronic version of the poster for viewing in the mobile app and onsite ePoster kiosks. Poster presentation guidelines will be shared with accepted authors.
- Authors – Identify the primary author and any additional co-authors. A maximum of 25 co-authors may be listed per abstract.
- Abstract Content & Requirements
  - Blind the body and title of the abstract appropriately. Any identifying information in the content or title fields will be cause for rejection.
  - Please note that the abstract submission system does not accept images or graphics.
  - Abstract content should be organized into the following sections: Introduction/Background, Methods, Results, and Conclusion. If a section does not apply, please put 'n/a' in that field.
  - Abstracts will be published as submitted without copyediting. Authors are responsible for ensuring accuracy, grammar, and correct spelling of names and credentials. Authors are strongly encouraged to draft their abstract in a program such as Microsoft Word or Google Docs that allows for spellcheck and grammatical review prior to inputting the content into the abstract submission system.
  - Abstract Text Limit: Up to 3,000 characters, cumulative, including spaces.



# 23<sup>rd</sup> Annual MEETING & EXPOSITION

September 23-26, 2026 • Glasgow, Scotland



- **Abstract Track** – Choose the category that best characterizes your abstract.
  - Cellular and T cell engager Immunotherapy (real life studies and sequencing)
  - MRD and Biomarkers
  - Myeloma Genomics and Microenvironment and Immune Profiling
  - Myeloma Novel Drug Targets and Agents
  - Plasma Cell Precursor and Other Disorders
  - Imaging, QoL and Patient-Reported Outcome and Supportive Care
  - Treatment of Newly Diagnosed Myeloma
  - Treatment of Relapsed/Refractory Myeloma
  - Nursing and Allied Health
- **Additional Information** – Answer these additional questions for each submitted abstract.
  - Preferred Presentation Format – Oral or Poster
  - If the preferred format is oral but the abstract is selected as a poster, indicate whether the abstract should be withdrawn
  - First time submitting an abstract to the IMS meeting
  - If you would like the abstract to be considered for the IMS Young Investigator Award. Eligibility criteria located [here](#).
- **Copyright** – IMS will hold the copyright for all accepted abstracts.

## Review Process

---

All abstracts will be blinded and peer reviewed according to specific criteria noted below. Poster presentations will be selected based on topic relevance, scientific quality, and available space. Abstracts that present information already widely available or previously disseminated may receive a lower review score.

Abstracts will be evaluated based on the following criteria:

- Relevance of the topic to the 23rd IMS Annual Meeting
- Scientific merits of the research
- Quality of the study design and data, and clarity of presentation
- Potential impact of the results on future research and/or clinical practice

## Withdrawal Requests

---

Abstracts must be withdrawn in the abstract submission system by July 6, 2026, to avoid publication in the program. Withdrawal requests submitted after this date must be sent via email to [imsabstracts@spargoinc.com](mailto:imsabstracts@spargoinc.com).

## Contact Us

---

For additional information, visit the 23rd IMS Annual Meeting website at [www.imsannual.com](http://www.imsannual.com) or contact the IMS abstracts team at [imsabstracts@spargoinc.com](mailto:imsabstracts@spargoinc.com).